ATXN2-mediated translation of TNFR1 promotes esophageal squamous cell carcinoma via m6A-dependent manner
Rui Li,Lingxing Zeng,Hongzhe Zhao,Junge Deng,Ling Pan,Shaoping Zhang,Guandi Wu,Ying Ye,Jialiang Zhang,Jiachun Su,Yanfen Zheng,Shuang Deng,Ruihong Bai,Lisha Zhuang,Mei Li,Zhixiang Zuo,Dongxin Lin,Jian Zheng,Xudong Huang
DOI: https://doi.org/10.1016/j.ymthe.2022.01.006
IF: 12.91
2022-03-01
Molecular Therapy
Abstract:N<sup>6</sup>-methyladenosine (m<sup>6</sup>A) is the most prevalent RNA modification, and the effect of its dysregulation on esophageal squamous cell carcinoma (ESCC) development remains unclear. Here, by performing transcriptome-wide m<sup>6</sup>A sequencing in 16 ESCC tissue samples, we identified the key roles of m<sup>6</sup>A in TNFRSF1A (also known as TNFR1)-mediated MAPK and NF-κB activation in ESCC. Mechanistically, a functional protein involved in m<sup>6</sup>A methylation, ATXN2, is identified that augments the translation of TNFRSF1A by binding to m<sup>6</sup>A-modified TNFRSF1A mRNA. Upregulation of the TNFRSF1A protein level, a vital upstream switch for TNFRSF1A-mediated signaling events, activates the NF-κB and MAPK pathways and thus promotes ESCC development. Furthermore, TNFRSF1A m<sup>6</sup>A modifications and protein levels are upregulated in ESCC, and high levels of TNFRSF1A m<sup>6</sup>A and protein are correlated with poor ESCC patient survival. These results collectively indicate that the m<sup>6</sup>A-TNFRSF1A axis is critical for ESCC development and thus may serve as a potential druggable target.
genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology